Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies

25 Mar, 2021

Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies
Photo by Sincerely Media on Unsplash

– Bioheng Biotech raised $80m in Series B financing.
– The round was led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with the participation of BlueRun Ventures and Shenzhen Capital Group Company.
– Proceeds will be used to advance R&D capabilities, process development and clinical trials.
– Bioheng is dedicated on developing novel cellular immunotherapy for cancer.

Asia Biopharma Biotechnology Clinical Trials Innovation Management
Crunchbase icon

Content report

The following text will be sent to our editors: